Dean Li, Merck Research Laboratories president
Merck highlights subcutaneous demand even as Keytruda sales soar
Merck said Keytruda sales jumped 21% to $6.6 billion in the fourth quarter of the year, driven by new approvals in earlier-stage indications for breast …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
